Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

DENTSPLY SIRONA Announces Pricing of $550M Notes

Dentsply Sirona Inc. (NASDAQ: XRAY) has announced the pricing of an offering of $550 million aggregate principal amount of its 8.375% junior subordinated notes due 2055. The notes will bear interest at a fixed rate of 8.375% per year until September 12, 2030, after which the interest rate will be reset based on the five-year U.S. Treasury rate plus a spread of 4.379%, with a floor of 8.375%.

The net proceeds from the offering will be approximately $544.5 million, which the company intends to use for general corporate purposes, including the repayment of existing indebtedness. The offering is expected to close on June 12, 2025, subject to customary closing conditions.

Goldman Sachs & Co. LLC is acting as the sole book-running manager for the offering, with PNC Capital Markets LLC, Commerz Markets LLC, Truist Securities, Inc., and MUFG Securities Americas Inc. acting as co-managers.

This offering follows the company's existing 364-day $435 million term loan and other short-term indebtedness. The offering is being made pursuant to an effective shelf registration statement on file with the U.S. Securities and Exchange Commission.

The company's decision to raise funds through this offering signifies its intention to address its financial obligations and pursue its operational and strategic objectives. Today the company's shares have moved -0.22% to a price of $15.865. For more information, read the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS